Clinical trial · Interventional
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of busulfan and melphalan followed by donor bone marrow transplantation in treating patients who have advanced hematologic cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Graft Versus Host Disease | — | UNRESOLVED | — |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Myelodysplastic/Myeloproliferative Neoplasms | Myelodysplastic/Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| allogeneic bone marrow transplantation | Procedure | — | UNRESOLVED |
| busulfan | Drug | Busulfan | ALIAS |
| melphalan | Drug | Melphalan | ALIAS |
| methotrexate | Drug | Methotrexate | ALIAS |
| tacrolimus | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of one of the following: * Infant leukemia * Acute lymphoblastic leukemia in 3rd or greater remission or relapse * Undifferentiated or biphenotypic leukemia in 2nd or greater remission or relapse * Juvenile chronic myelogenous leukemia (CML) * Acute myelogenous leukemia (AML) in 3rd or greater remission or relapse * Primary advanced myelodysplastic syndrome (MDS) excluding refractory anemia (RA) and RA with ringed sideroblasts * Therapy-related MDS of any stage or AML * CML in 2nd or greater chronic phase, accelerated, or blastic phase * Acute leukemia, CML, or MDS but unable to tolerate total body irradiation (TBI) due to potential neurotoxicity (prior TBI, prior local radiotherapy,or under 2 years of age) * No active CNS disease * Related or unrelated bone marrow donor matched at HLA-A, B, and DR beta 1 PATIENT CHARACTERISTICS: Age: * Under 60 (over 60 considered on case-by-case basis) Performance status: * Karnofsky 70-100% * Lansky 70-100% Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * AST and ALT less than 2 times upper limit of normal * Bilirubin less than 1.5 mg/dL unless liver is involved with disease Renal: * Creatinine normal * Creatinine clearance greater than 60 mL/min Cardiovascular: * Asymptomatic with no prior risk factors OR * LVEF greater than 50% if symptomatic Pulmonary: * Asymptomatic with no prior risk factors OR * Diffusion capacity greater than 50% predicted (corrected for hemoglobin) if symptomatic Other: * No active uncontrolled viral, bacterial, or fungal infection * Not pregnant or nursing * Negative pregnancy test * HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy: * More than 6 months since prior allogeneic or autologous stem cell transplantation Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics Surgery: * Not specified
References
Publications (0)
Data not yet available